HC Wainwright reissued their buy rating on shares of Innate Pharma (NASDAQ:IPHA – Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for Innate Pharma’s FY2030 earnings at $0.42 EPS. Several other brokerages also recently commented on IPHA. […]